In-vitro diagnosis and bio-healthcare services

We’re developing innovative products and services focusing on the prevention and diagnosis of diseases, and monitoring patients using various types and forms of nanoparticles such as Graphene, Carbon Nanotube, Magnetic Beads, etc.

Femtech Supplies for women

We have been R&D and newly commercializing Femtech Products for women life better, along with varied shape of feminine cleansers & wipes and medical devices as pregnancy testers, ovulation testers, vaginitis test kit and urethritis test kit etc.

Rivoceranib

Rivoceranib is an oral anticancer drug that has therapeutic effects on many solid tumors. It is a targeted therapy which selectively inhibits Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). HLB-LS has exclusive right for development and sales of Rivoceranib in Korea, and partial rights in Japan and Europe. It submitted NDA to FDA as a first-line treatment option for Hepatocellular Carcinoma in May 2023.

Pyrotinib

Pyrotinib is a targeted anticancer drug that effectively inhibits the EGFR family (EGFR, HER2, HER4). It has demonstrated anticancer effects on HER2-positive advanced solid cancer. HLB-LS is planning more clinical trials to confirm the effectiveness of Pyrotinib on various solid tumors involving HER2.

G2M inhibitor

G2M inhibitor interferes with the progression of G2 to M stage during the cell cycle(inhibiting the growth of cancer cells and inducing cell death). HLB-LS is conducting the nonclinical stage for the treatment of solid tumors.

CDK inhibitor

CDK (Cyclin-dependent kinase) is a key enzyme in a cell cycle. It inhibits Ser/Thr kinase that controls transcription by the activation of RNA polymerase II, thereby preventing the self-repair mechanism of cancer cells and inducing damage to cancer cells. HLB-LS is conducting screening research to identify druggable candidates for solid tumors.

Cannabinoid-derived anticancer drug

Cannabinoids have anticancer properties, which can improve cancer therapy. This project determines the potential utility of cannabinoids in the treatment of cancer. HLB-LS is researching to discover new candidates for the treatment of solid tumors through the screening of various cannabinoid derivatives.

Treatments for ocular diseases

RGN-259 is an ophthalmic solution with Thymosin β4 as its active ingredient, exhibiting wound healing and anti-inflammatory effects. It is currently under development by the U.S.-based joint venture, ReGenTree, LLC. The treatment for Dry Eye Disease (DED) is suitable for multifactorial diseases related to tear deficiency or excessive tear evaporation and is under phase 3 study. The treatment for Neurotrophic Keratitis (NK) is appropriate for degenerative corneal diseases with corneal epithelial damage, ulcers, and perforations. It has been designated as an orphan drug by the FDA, and two phase 3 clinical trials are ongoing in the U.S. and Europe.

Glioblastoma multiforme (GBM) treatment

Glioblastoma multiforme (GBM) is a malignant brain tumor that originates from cells present in the brain tissue. OKN-007 has effects that enhance the tumor microenvironment, inhibiting the immunosuppressive effects of cancer treatments, reducing hypoxia-induced occurrences, and suppressing the formation of new blood vessels by cancer cells. Additionally, it temporarily opens the blood- brain barrier (BBB) to improve drug penetration. It has been designated as an orphan drug by the FDA, and the U.S.-based corporation, Oblato, Inc., is currently conducting phase 2 trials for recurrent GBM and an investigator-initiated trial for a newly diagnosed GBM.

Cold chain business

The cold chain business refers to the distribution of pharmaceuticals that require low-temperature handling, maintaining a specific temperature throughout their transit. Especially in 2022, with the strengthening of pharmaceutical distribution and sales management, the distribution of biological medicines through cold chain infrastructure has become mandatory. Our company, as the sole distributor of the public Covid-19 vaccine in 2023, is equipped with a nationwide cold chain system. Additionally, we are engaged in the distribution of blockbuster vaccines for influenza, shingles, pneumococcus, cervical cancer, and M-POX.

척추소뇌변성증 치료제 임상4상(씨트렐린 구강붕해정)

소뇌를 구성하는 세포들이 알 수 없는 기전으로 사멸하는 희귀질환으로 운동 실조가 주요한 증상입니다. 대규모 임상을 통한 효과와 안전성을 확보한 치료제가 없는 상황에서, 국내 8개 대형 대학병원에서 166명의 환자를 상대로 유효성 평가 및 확립을 입증하는 임상 4상을 진행 중 입니다.

Namyangju Factory 1

Hyangnam Factory 2

Human extracellular matrix, Hutrigel®

Hutrigel is a human normal extracellular matrix containing basement membrane components produced through large-scale cell culture, which serves as a scaffold in tissues and organs. It is intended for use in stem cell /organoid research and as a functional material for tissue and organ regeneration.

Hemostat, BleeFix®

A powder-type hemostat w it h excellent biocompatibility and superior hemostatic properties. It c an be used not only for various external hemorrhages but also during surgeries .

Bio-Bio-artificial liver, LifeLiver®

LifeLiver® is a cell therapy for extending the golden time for patients with acute liver failure who are waiting for a liver transplant.

Supplying primary human hepatocytes, LifeHepa™

For the first time among domestic companies, we provide a service that supplies primary hepatocytes from human livers for drug metabolism and pharmacokinetic testing of new drug candidates..